Geneva, March 20 -- International Clinical Trials Registry received information related to the study (NCT07457164) titled 'A Study Investigating the Pharmacokinetics, Pharmacodynamics, Efficacy and Safety of Teverelix DP, a Gonadotropin-releasing Hormone (GnRH) Antagonist, in Patients With Advanced Prostate Cancer' on Feb. 24.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Antev Ltd.
Condition:
Advanced Prostate Cancer
GnRH Antagonist
Intervention:
Drug: Teverelix DP 180 mg
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment: July 2026
Target Sample Size: 40
To know more, ...